Biotech Analyst Karnauskas, along with Dr. Anton Porsteinsson, discuss the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) impact on Leqembi (Eisai & Biogen) on an Analyst/Industry conference call to be held on April 12 at 9:45 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Drugmakers call for abortion pill ruling reversal, Reuters reports
- FDA AdCom to convene on June 9th to discuss Biogen/Eisai’s LEQEMBI in AD
- JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data
- Biogen appoints Keeney as Head of Corporate Development
- Biogen Appoints Adam Keeney as Head of Corporate Development